Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GIM-407 in healthy volunteers
NCT06536101Phase 1Completed
- Sponsor
- Georgiamune
- Start
- Sep 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune disease, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE) and 1 more comparing GIM-407 with Placebo (2 arms). Primary endpoint: Evaluation of Safety. Started Sep 2024; status: completed.
02
Drugs
GIM-407
03
Conditions
autoimmune diseaseinflammatory bowel disease (IBD)systemic lupus erythematosus (SLE)type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06536101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536101.